![JRFM | Free Full-Text | Founding Family Ownership and Firm Performance: Some Evidence from the Italian Stock Market JRFM | Free Full-Text | Founding Family Ownership and Firm Performance: Some Evidence from the Italian Stock Market](https://www.mdpi.com/jrfm/jrfm-15-00231/article_deploy/html/images/jrfm-15-00231-g001.png)
JRFM | Free Full-Text | Founding Family Ownership and Firm Performance: Some Evidence from the Italian Stock Market
A Recordati il Premio “Eccellenze d'Impresa 2016” di Gea e Harvard Business Review Italia - Hbr Italia
Recordati, agreement with GSK for Avodart Combodart distribution in Europe -July 20, 2023 at 12:26 pm EDT | MarketScreener
![Recordati in cima al Ftse Mib, perché l'accordo con GSK è interessante sotto il profilo strategico e finanziario - MilanoFinanza News Recordati in cima al Ftse Mib, perché l'accordo con GSK è interessante sotto il profilo strategico e finanziario - MilanoFinanza News](https://www.milanofinanza.it/remote/static.milanofinanza.it/content_upload/img/2023/07/202307211110022409/Recordati-626369.jpg?w=403&h=226&mode=crop&anchor=topcenter&format=jpg&quality=75)
Recordati in cima al Ftse Mib, perché l'accordo con GSK è interessante sotto il profilo strategico e finanziario - MilanoFinanza News
![The Relevance of Climate Change Related Risks on Corporate Financial and Non-Financial Disclosure in Italian Listed Companies | SpringerLink The Relevance of Climate Change Related Risks on Corporate Financial and Non-Financial Disclosure in Italian Listed Companies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/chp%3A10.1007%2F978-3-030-14548-4_4/MediaObjects/978-3-030-14548-4_4_Fig5_HTML.png)
The Relevance of Climate Change Related Risks on Corporate Financial and Non-Financial Disclosure in Italian Listed Companies | SpringerLink
![Recordati: conti battono le attese. Nei nove mesi ricavi per €1,38 mld (+19,1%). Rivista al rialzo Guidance 2022 e proposto acconto su dividendo 2023 - Borse.it Recordati: conti battono le attese. Nei nove mesi ricavi per €1,38 mld (+19,1%). Rivista al rialzo Guidance 2022 e proposto acconto su dividendo 2023 - Borse.it](https://cdn.borse.it/nspbJbTgyAZ5CrtjEZ2pnPHd84Y=/656x492/smart/https://www.borse.it/app/uploads/2022/11/borsa-italiana-piazza-affari-milano-95390419.jpg)
Recordati: conti battono le attese. Nei nove mesi ricavi per €1,38 mld (+19,1%). Rivista al rialzo Guidance 2022 e proposto acconto su dividendo 2023 - Borse.it
![1997 First launch of Zanidip (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. - PDF Free Download 1997 First launch of Zanidip (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. - PDF Free Download](https://docplayer.net/docs-images/80/80722865/images/43-0.jpg)
1997 First launch of Zanidip (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. - PDF Free Download
![1997 First launch of Zanidip (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. - PDF Free Download 1997 First launch of Zanidip (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. - PDF Free Download](https://docplayer.net/docs-images/80/80722865/images/22-0.jpg)
1997 First launch of Zanidip (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. - PDF Free Download
![Equita: Recordati rischia un -50 mln di fatturato nel 2022 e il titolo scivola in borsa - MilanoFinanza News Equita: Recordati rischia un -50 mln di fatturato nel 2022 e il titolo scivola in borsa - MilanoFinanza News](https://www.milanofinanza.it/remote/static.milanofinanza.it/content_upload/img/2022/03/202203181144545005/Recordati-101846.png?w=403&h=226&mode=crop&anchor=topcenter&format=jpg&quality=75)